King Minos II hall
King Minos III hall
_edited_edited_edited.jpg){kind=small}
Poster session
N.1A. e-Poster
Breakthrough in Nephrology
N.2A. Changing the status quo in CKD
1. SGLT2 inhibitors: what's new?
2. The place of GLP-1 agonists in clinical practice
3. The place of MRAs in clinical practice
Hypertension
N.3A. Hypertension
1. Management of hypertension in patients with CKD
2. Resistant hypertension
3. Use of diuretics in CKD: benefits and risks
Cardiovascular morbidity
N.5A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new?
2. Challenges in the management of heart failure in patients with CKD
3. Update in the management of hyperkalaemia
Clinical Nephrology
N.4A. IgA nephropathy
1. The role of B cells and BAFF/APRIL
2. New and emerging therapies in IgA nephropathy
3. How should I manage the patient with IgA nephropathy
General assembly
Hereditary nephropathies
N.6A. Polycystic kidney disease
1. Safety and effectiveness of Tolvaptan
2. New KDIGO Guidelines
3. Genetic tests: what should I know?
N.7A. Other hereditary nephropathies
1. Fabry Disease: what should I know?
2. Type-4 collagen gene mutation related nephropathies
3. Hereditary tubulointerstitial nephropathies
Haemodialysis
N.8A. Haemodialysis
1. Management of bone mineral disease: what is the target and how to achieve it
2. Uremic pruritus: systematic review, evaluation and management
3. HIF inhibitors: their place in clinical practice
Lunch
Close